Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases.
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. The company identifies and selects lead vaccine candidates through its proprietary affinity optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within the industry, academia, and the government sector through NIAID.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 13, 2018 | Grant | $2.30M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Cancer Research Institute | — | Grant |